FDA Guides Faster Path for Generic Drug Approvals
Published Date: 6/16/2025
Notice
Summary
The FDA just released new rules to help generic drug makers send important info about their factories before submitting priority drug applications. This speeds up reviews and helps the FDA set clear goals for fast-tracking these drugs. If you’re in the generic drug business, get ready to share your facility details early to keep things moving smoothly and meet new deadlines tied to the latest fee program.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Send Factory Details Before Priority ANDAs
The FDA's final guidance explains what facility information generic drug makers must send in a pre-submission facility correspondence (PFC) before filing a prioritized Abbreviated New Drug Application (ANDA). The guidance explains how FDA will use that facility information to set a review goal for a priority ANDA.
Guidance Implements GDUFA III Enhancement
The guidance incorporates a program enhancement agreed between FDA and industry as part of the Generic Drug User Fee Amendments (GDUFA) reauthorization and described in the GDUFA III commitment letter for Fiscal Years 2023-2027. The document finalizes the draft guidance that was issued on December 5, 2022.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20441, Medical Devices; Cardiovascular Devices; Classification of the Hyperoxia Monitoring Device Adjunct to Pulse Oximetry
The FDA is officially putting the hyperoxia monitoring device that works with pulse oximeters into a safer, easier-to-manage category called Class II. This change, effective October 6, 2026, means the device will have special safety rules but fewer regulatory hurdles, helping patients get access to this cool tech faster. Medical device makers and healthcare providers will feel the impact, with smoother approval processes and no big new costs expected.
Previous / Next Documents
Previous: 2025-10921, Government-Owned Inventions; Availability for Licensing
The U.S. Government owns some cool inventions and is ready to license them out so companies can bring them to market faster. This means businesses can grab rights to use these inventions, including some with international patent protection. If you’re a company looking to innovate, now’s the time to check out these opportunities and get in on the action!
Next: 2025-10923, Applications for Membership to the American Fisheries Advisory Committee
The Secretary of Commerce is looking for 7 new members to join the American Fisheries Advisory Committee, which helps guide fishing policies. If you love fish and want to make a difference, now’s your chance! Members will serve for three years, so get ready to dive into some important work soon.